Terry Wells, MD
Family Medicine · Lufkin, TXNPI 1639104813
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $969 of the $1,129 with a category attached, or 85.9%. It is spread thinly across 20 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $397 and has fallen 63.2% since, to $146 in 2024.
Across 58 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascensia Diabetes Care US Inc.$159
- Pfizer$137
- AstraZeneca$124
- Boehringer Ingelheim$97
- Novo Nordisk$95
- GSK$94
- plus $423 from 14 others
Across 41 payments — averaging $9910.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$325K
- AstraZeneca$34K
- American Regent$25K
- Merck$12K
- Teva Pharmaceuticals USA, Inc.$11K
What the payments were for
- Food & beverage$96986%
- Education$15914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascensia Diabetes Care US Inc. | 1 | $159 |
| Pfizer | 8 | $137 |
| AstraZeneca | 8 | $124 |
| Boehringer Ingelheim | 5 | $97 |
| Novo Nordisk | 6 | $95 |
| GSK | 5 | $94 |
| Mylan Specialty L.p. | 4 | $90 |
| AbbVie | 4 | $63 |
| Lilly USA, LLC | 4 | $62 |
| Bayer | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Almatica Pharma LLC | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
How this compares
$1,129 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 87 | $61,278 |
| OzempicSemaglutide | 50 | $48,679 |
| RybelsusSemaglutide | 28 | $44,919 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $35,393 |
| TradjentaLinagliptin | 41 | $20,209 |
| JardianceEmpagliflozin | 15 | $16,130 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 18 | $13,200 |
| MyrbetriqMirabegron | 17 | $10,948 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,234 |
| SynthroidLevothyroxine Sodium | 53 | $3,384 |
| Valsartan | 124 | $3,199 |
| Raloxifene Hcl | 40 | $2,919 |
| Gabapentin | 237 | $2,852 |
| Pregabalin | 44 | $2,307 |
| Tizanidine Hcl | 63 | $2,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $95 | $93,59978 claims |
| AstraZenecaFarxiga | $124 | $61,27887 claims |
| Boehringer IngelheimTradjenta, Jardiance, Trijardy Xr | $97 | $49,53974 claims |
| GSKTrelegy Ellipta | $94 | $35,39339 claims |
| AbbVieSynthroid | $63 | $3,38453 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Lufkin
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.